Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 23322858.
- Also identified by DOI 10.1093/infdis/jit025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Levels of soluble CD14 (sCD14) were longitudinally measured in 85 human immunodeficiency virus (HIV)-infected subjects during long-term receipt of suppressive combined antiretroviral therapy (cART) and compared to those in young and elderly HIV-negative control subjects. cART did not normalize sCD14 levels; rather, the HIV-infected group displayed a significantly higher sCD14 level at baseline (ie, before cART initiation), 1 year after cART initiation, and 5 years after cART initiation, compared with both control groups. Furthermore, the baseline CD4(+) T-cell count was inversely associated with the baseline sCD14 level. Our results point to the necessity of complementary therapies to treat the activated/inflamed status associated with chronic HIV infection and to the benefits of early initiation of cART.
Medical subject headings
- Anti-Retroviral Agents
- Cyclohexanes
- HIV Infections
- Lipopolysaccharide Receptors
- Triazoles